Please use this identifier to cite or link to this item:
|Title:||Effect of statin use during hospitalization for intracerebral hemorrhage on mortality and discharge disposition.|
|Authors:||Flint, Alexander C;Conell, Carol;Rao, Vivek A;Klingman, Jeff G;Sidney, Stephen;Johnston, S Claiborne;Hemphill, J Claude;Kamel, Hooman;Davis, Stephen M;Donnan, Geoffrey A|
|Affiliation:||Department of Neuroscience, Kaiser Permanente Northern California, Redwood City, California.|
Department of Neurology, Kaiser Permanente, Walnut Creek, California.
Division of Research, Kaiser Permanente Northern California, Oakland, California.
Dell Medical School, University of Texas, Austin.
Department of Neurology, University of California, San Francisco.
Department of Neurology, Weill Cornell Medical College, New York, New York7Department of Neuroscience, Weill Cornell Medical College, New York, New York.
Department of Neurology, Royal Melbourne Hospital, University of Melbourne, Parkville, Melbourne, Victoria, Australia.
Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Melbourne, Victoria, Australia.
|Citation:||Jama Neurology; 71(11): 1364-71|
|Abstract:||Statin use during hospitalization is associated with improved survival and a better discharge disposition among patients with ischemic stroke. It is unclear whether inpatient statin use has a similar effect among patients with intracerebral hemorrhage (ICH).To determine whether inpatient statin use in ICH is associated with improved outcomes and whether the cessation of statin use is associated with worsened outcomes.Retrospective cohort study of 3481 patients with ICH admitted to any of 20 hospitals in a large integrated health care delivery system over a 10-year period. Detailed electronic medical and pharmacy records were analyzed to explore the association between inpatient statin use and outcomes.The primary outcome measures were survival to 30 days after ICH and discharge to home or inpatient rehabilitation facility. We used multivariable logistic regression, controlling for demographics, comorbidities, initial severity, and code status. In addition, we used instrumental variable modeling to control for confounding by unmeasured covariates at the individual patient level.Among patients hospitalized for ICH, inpatient statin users were more likely than nonusers to be alive 30 days after ICH (odds ratio [OR], 4.25 [95% CI, 3.46-5.23]; P < .001) and were more likely than nonusers to be discharged to their home or an acute rehabilitation facility (OR, 2.57 [95% CI, 2.16-3.06]; P < .001). Patients whose statin therapy was discontinued were less likely than statin users to survive to 30 days (OR, 0.16 [95% CI, 0.12-0.21]; P < .001) and were less likely than statin users to be discharged to their home or an acute rehabilitation facility (OR, 0.26 [95% CI, 0.20-0.35]; P < .001). Instrumental variable models of local treatment environment (to control for confounding by unmeasured covariates) confirmed that a higher probability of statin therapy was associated with a higher probability of 30-day survival (with an increase in probability of 0.15 [95% CI, 0.04-0.25]; P = .01) and a better chance of being discharged to home or an acute rehabilitation facility (with an increase in probability of 0.13 [95% CI, 0.02-0.24]; P = .02).Inpatient statin use is associated with improved outcomes after ICH, and the cessation of statin use is associated with worsened outcomes after ICH. Given the association between statin cessation and substantially worsened outcomes, the risk-benefit balance of discontinuing statin therapy in the acute setting of ICH should be carefully considered.|
|Internal ID Number:||25244578|
Aged, 80 and over
Cerebral Hemorrhage.drug therapy.mortality
Hydroxymethylglutaryl-CoA Reductase Inhibitors.therapeutic use
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.